SOBR Safe, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SOBR Safe, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $437.4K | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $212.7K | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $157.3K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $35.3K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 31, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $235.5K | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $19.2K | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $62.4K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $16.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.95M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($8.61M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($10.21M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($12.35M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($7.87M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($29.98M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.25M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($559.0K) | May 26, 2020 |
| FY2018 | Dec 31, 2017 | ($642.3K) | Aug 8, 2019 |
| FY2017 | Dec 31, 2016 | ($595.1K) | Feb 6, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.16M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($7.68M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($9.60M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($10.41M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.56M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($28.27M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($787.3K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($299.0K) | May 26, 2020 |
| FY2018 | Dec 31, 2017 | ($313.1K) | Aug 8, 2019 |
| FY2017 | Dec 31, 2016 | ($396.1K) | Feb 6, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $329.7K | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $747.5K | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.02M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.40M | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $566.7K | Mar 11, 2022 |
| FY2021 | Dec 31, 2020 | $633.1K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $12.8K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $8.9K | May 26, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.96M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($6.52M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($5.93M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($6.16M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.69M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.19M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($544.0K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($61.4K) | May 26, 2020 |
| FY2018 | Dec 31, 2017 | ($162.6K) | Aug 8, 2019 |
| FY2017 | Dec 31, 2016 | ($131.5K) | Feb 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.2K | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 10, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.62M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $11.17M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $6.15M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $11.91M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.21M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.99M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $690.8K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $13.1K | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.1K | Aug 8, 2019 |
| FY2017 | Dec 31, 2016 | $14.3K | Feb 6, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.70M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.37M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $4.16M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.82M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.69M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $947.1K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $4.28M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.44M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.97M | Aug 8, 2019 |
| FY2017 | Dec 31, 2016 | $3.03M | Feb 6, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $9.86M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $2.04M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $9.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($483.6K) | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $3.04M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($3.59M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | ($3.42M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($2.96M) | May 26, 2020 |
| FY2017 | Dec 31, 2016 | ($3.01M) | Feb 6, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($107.33M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($98.33M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($87.77M) | Apr 15, 2025 |
| FY2023 | Jan 1, 2023 | $776.6K | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($78.33M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($57.47M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($49.60M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($19.51M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($18.26M) | May 26, 2020 |
| FY2018 | Dec 31, 2017 | ($17.70M) | Aug 8, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $882.3K | Mar 11, 2022 |
| FY2021 | Dec 31, 2020 | $232.8K | Mar 11, 2022 |
| FY2021 | Dec 31, 2019 | $681.8K | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $89 | Mar 31, 2021 |
| FY2018 | Dec 31, 2017 | $142 | Aug 8, 2019 |
| FY2018 | Dec 31, 2016 | $14.3K | Aug 8, 2019 |
| FY2017 | Dec 31, 2015 | $7.9K | Feb 6, 2019 |
| FY2016 | Dec 31, 2014 | $623 | Apr 17, 2017 |
| FY2014 | Dec 31, 2012 | $782 | Apr 15, 2015 |
| FY2013 | Dec 31, 2011 | $108.0K | Apr 15, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $979.9K | Apr 15, 2014 |
| FY2012 | Dec 31, 2012 | $979.9K | May 9, 2013 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 172 | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | (619) | Apr 15, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.89M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 936,926 | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 16,895 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 16.98M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 8.78M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 25.92M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 6.45M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 109.41M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | 109.41M | Aug 8, 2019 |
| FY2017 | Dec 31, 2016 | 67.75M | Feb 6, 2019 |